Progression-Free Survival Data for Investigational Afatinib and Nintedanib

Nintedanib is being evaluated in various solid tumors – including advanced NSCLC, ovarian cancer, liver cancer (hepatic cell carcinoma), kidney cancer (renal cell carcinoma) and colorectal cancer.05/16/2013
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news